ACHL:NSD-Achilles Therapeutics PLC ADR (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.90

Change

-0.03 (-1.55)%

Market Cap

USD 0.08B

Volume

3.28K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ACHL Stock Forecast & Price:
Based on the Achilles Therapeutics PLC ADR stock forecasts from 0 analysts, the average analyst target price for Achilles Therapeutics PLC ADR is not available over the next 12 months. Achilles Therapeutics PLC ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Achilles Therapeutics PLC ADR is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Achilles Therapeutics PLC ADR’s stock price was USD 1.90. Achilles Therapeutics PLC ADR’s stock price has changed by +5.56% over the past week, -6.40% over the past month and -61.54% over the last year.

About Achilles Therapeutics PLC ADR (ACHL:NSD)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advan ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.03 (+0.33%)

USD80.34B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

-5.40 (-0.73%)

USD80.18B 15.51 11.82
MRNA Moderna Inc

-2.23 (-1.27%)

USD67.38B 6.33 4.43
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.12 (+1.31%)

USD37.58B 3.75 1.66
GMAB Genmab AS

-0.52 (-1.16%)

USD29.87B 37.36 3.53
ALNY Alnylam Pharmaceuticals Inc

-4.41 (-2.11%)

USD26.17B N/A -26.97
SGEN Seagen Inc

-3.85 (-3.18%)

USD22.92B 55.02 -38.67
ARGX argenx NV ADR

-1.28 (-0.34%)

USD21.49B N/A -20.63
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACHL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -62.08% 43% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.08% 43% F 26% F
Trailing 12 Months  
Capital Gain -62.75% 48% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.75% 48% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.61% 23% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.61% 23% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 34.75% 68% D+ 46% F
Risk Adjusted Return -79.45% 23% F 9% F
Market Capitalization 0.08B 43% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.30 80% B- 95% A
Price/Book Ratio 0.36 94% A 94% A
Price / Cash Flow Ratio -1.33 37% F 52% F
EV/EBITDA 1.32 9% F 39% F
Management Effectiveness  
Return on Equity -25.74% 84% B 41% F
Return on Invested Capital -26.82% 74% C 32% F
Return on Assets -16.60% 79% C+ 30% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.26 78% C+ 68% D+
Short Percent 3.59% 48% F 39% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.